List of Excipients in Branded Drug FERRIC CITRATE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	FERRIC CITRATE	ferric citrate	0378-2895	CALCIUM STEARATE
Mylan Pharmaceuticals Inc	FERRIC CITRATE	ferric citrate	0378-2895	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	FERRIC CITRATE	ferric citrate	0378-2895	FD&C RED NO. 40
Mylan Pharmaceuticals Inc	FERRIC CITRATE	ferric citrate	0378-2895	FD&C YELLOW NO. 6
Mylan Pharmaceuticals Inc	FERRIC CITRATE	ferric citrate	0378-2895	HYPROMELLOSE 2910

Generic Drugs Containing FERRIC CITRATE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	ferric citrate	0480-2996	CALCIUM STEARATE
Teva Pharmaceuticals Inc	ferric citrate	0480-2996	FD&C BLUE NO. 2 ALUMINUM LAKE
Teva Pharmaceuticals Inc	ferric citrate	0480-2996	FD&C RED NO. 40 ALUMINUM LAKE
Teva Pharmaceuticals Inc	ferric citrate	0480-2996	FD&C YELLOW NO. 6 ALUMINUM LAKE
Teva Pharmaceuticals Inc	ferric citrate	0480-2996	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in FERRIC CITRATE?

# Of NDCs	Excipient
1	CALCIUM STEARATE
1	FD&C BLUE NO. 2 ALUMINUM LAKE
1	FD&C RED NO. 40 ALUMINUM LAKE
1	FD&C YELLOW NO. 6 ALUMINUM LAKE
1	HYPROMELLOSE 2910

# Ferric Citrate Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Ferric citrate has a differentiated formulation profile because the active ingredient is both an iron source and a phosphate binder. The leading U.S. product, Auryxia, is a film-coated tablet containing 210 mg of ferric iron, equivalent to approximately 1 g of ferric citrate per tablet. Its commercial opportunity is concentrated in chronic kidney disease, dialysis-related hyperphosphatemia, and iron-deficiency anemia in adults with nondialysis chronic kidney disease. Excipient innovation is most valuable when it reduces pill burden, improves gastrointestinal tolerability, controls iron release, or enables alternative dosage forms.

A successful product strategy must preserve ferric citrate’s phosphate-binding performance while managing taste, tablet size, iron-related discoloration, gastrointestinal adverse events, and manufacturing variability. Generic competition is possible through an abbreviated new drug application, but differentiated formulations may require a 505(b)(2) pathway or new clinical support.

What is the FDA-approved ferric citrate formulation?

Auryxia is approved in the United States for two indications:

Attribute	Auryxia data
Active ingredient	Ferric citrate coordination complex
Strength	210 mg ferric iron per tablet
Approximate ferric citrate content	1 g per tablet
Dosage form	Oral film-coated tablet
U.S. sponsor	Akebia Therapeutics, through its Auryxia franchise
Initial FDA approval	September 2014
Hyperphosphatemia indication	Adults with chronic kidney disease on dialysis
Iron-deficiency indication	Adults with chronic kidney disease not on dialysis
Administration	Taken with meals for phosphate control
Principal commercial issue	High chronic pill burden and gastrointestinal tolerability

The FDA label identifies conventional tablet excipients, including microcrystalline cellulose, crospovidone, magnesium stearate, hypromellose, polyethylene glycol, talc, and titanium dioxide. The exact qualitative and quantitative formulation should be confirmed against the current approved labeling and regulatory filing before development decisions are made (U.S. Food and Drug Administration [FDA], 2024).

Ferric citrate is not a conventional small-molecule active that can be freely substituted with another iron salt. Its performance depends on iron coordination, dissolution, phosphate interaction, gastric conditions, and the amount of elemental iron delivered. Excipient changes can therefore alter both the active pharmaceutical ingredient’s clinical function and the product’s regulatory profile.

What excipient functions matter most for ferric citrate?

The highest-value excipient functions are tablet compression, wetting, disintegration, release control, taste management, film coating, and gastrointestinal tolerability.

Tablet mass and compression

Ferric citrate products contain a high active load. A 210-mg elemental iron dose corresponds to roughly 1 g of ferric citrate before accounting for excipients and coating. This creates a large tablet and limits the amount of conventional excipient that can be added without increasing tablet burden.

Direct-compression systems based on microcrystalline cellulose, silicified microcrystalline cellulose, coprocessed cellulose, or compressible polyols can improve tablet strength at lower excipient loading. The commercial objective is not simply a smaller tablet. It is a smaller total daily dose burden while maintaining adequate hardness, friability, dissolution, and phosphate-binding activity.

Disintegration and wetting

Crospovidone and related superdisintegrants can improve water penetration into a high-load ferric citrate matrix. Excessive disintegration, however, may change the local concentration of iron in the gastrointestinal tract and affect tolerability.

Potential development variables include:

• Superdisintegrant type and concentration
• Granulation versus direct compression
• Tablet porosity
• Lubricant concentration and mixing time
• Particle-size distribution of ferric citrate
• Surface area and wetting behavior
• Dissolution in physiologically relevant media

A ferric citrate formulation should be tested in media that reflect gastric and intestinal pH, phosphate concentration, food conditions, and the presence of other orally administered medicines.

Film coating

Film coating has several commercial functions:

1. Masking metallic or astringent taste.
2. Reducing handling-related iron staining.
3. Improving swallowability.
4. Protecting the tablet from moisture.
5. Supporting product identification and adherence.
6. Controlling initial wetting without creating an enteric dosage form.

A coating that delays exposure too aggressively could reduce phosphate-binding activity in the stomach. An enteric-coated ferric citrate product would require strong clinical and mechanistic justification because phosphate binding is intended to occur during gastrointestinal transit and is closely linked to meal administration.

Gastrointestinal tolerability

Abdominal pain, diarrhea, constipation, nausea, and stool discoloration are commercially relevant attributes for iron-containing products. Excipients can influence local iron exposure, transit, osmotic effects, and tablet breakup.

Potential strategies include:

• Lower peak local concentration through multiparticulates
• Controlled release that does not materially impair phosphate binding
• Reduced free-iron exposure through particle engineering
• Mucoadhesive or protective coating systems
• Alternative binders with lower lubricant requirements
• Formulations that reduce tablet disintegration variability

Any strategy that changes iron exposure must distinguish between tolerability improvement and reduced therapeutic activity. Ferric citrate’s value comes from gastrointestinal iron and phosphate interaction, so reducing exposure too far could undermine both indications.

What formulations are protected or commercially attractive for ferric citrate?

The most attractive formulation opportunities are those that solve operational problems in dialysis and chronic kidney disease treatment.

Smaller or higher-load tablets

Patients receiving dialysis may take multiple phosphate-binding tablets with each meal. A higher-load formulation could reduce the number of tablets per meal, provided that elemental iron delivery and phosphate binding remain controlled.

Commercial value would be highest for a product that demonstrates:

• Equivalent phosphate reduction at a lower tablet count
• Comparable or improved iron parameters
• No increase in gastrointestinal adverse events
• Equivalent or better medication adherence
• Stable performance with common dialysis diets

This type of product could support a new patent estate covering composition, particle size, compression parameters, or dose regimen. It would not automatically receive brand-level market exclusivity if the claims merely cover routine optimization.

Chewable tablets

A chewable ferric citrate product could address swallowing difficulty and reduce the need to take a large tablet with meals. Taste masking is the main technical barrier. Ferric salts and iron complexes can produce metallic, mineral, or astringent taste profiles.

Suitable systems may include:

• Polymeric taste-masking coatings
• Ion-exchange resins
• Lipid-based barriers
• Complex carbohydrates
• Sweetener and flavor systems
• Rapidly dispersible granules

The formulation must avoid excessive binding of ferric citrate in a way that reduces phosphate interaction. A chewable version would also require evaluation of dental staining, residual iron taste, and dosing accuracy.

Sachets, granules, and sprinkle products

Granules or sachets could improve administration for patients with dysphagia and create opportunities in institutional, dialysis-center, and home-care settings. These formats can be mixed with soft food, but their stability and dose uniformity must be tightly controlled.

Key development risks include segregation, moisture uptake, iron oxidation, discoloration of food, and incomplete consumption. A sprinkle product also requires clear instructions for food compatibility and administration timing.

Combination products

Ferric citrate could be combined with agents that address adjacent chronic kidney disease needs, but combination development is complex. Potential targets include vitamin D analogs, potassium-management products, or other mineral-bone disorder therapies.

The principal barriers are:

• Drug-drug binding in the gastrointestinal tract
• Conflicting administration instructions
• Increased regulatory complexity
• Higher risk of dose titration errors
• Difficulty attributing adverse events
• Potential interference with absorption of concomitant medicines

A fixed-dose combination is more commercially plausible when the co-administered product has a stable dosing relationship with ferric citrate. A co-packaged regimen may offer a lower-risk alternative.

When does ferric citrate lose exclusivity?

U.S. exclusivity for ferric citrate depends on several separate mechanisms:

Exclusivity category	Ferric citrate relevance
New chemical entity exclusivity	The original approval did not operate as a typical five-year NCE launch because ferric citrate had prior regulatory and clinical history
Three-year clinical investigation exclusivity	Relevant to the 2014 approval and subsequent indication expansion
Orphan-drug exclusivity	Not the principal basis for Auryxia’s commercial protection
Orange Book patents	The principal barrier to ANDA approval and launch timing
Formulation patents	May extend protection beyond the original active-ingredient claims
Method-of-use patents	May cover hyperphosphatemia, iron deficiency, dosing, or patient populations
Pediatric exclusivity	Depends on an FDA-granted pediatric extension and current listing

The earliest Auryxia patents were filed before the 2014 approval and have expirations that fall in the mid-to-late 2020s, depending on patent-term adjustment, patent-term extension, and the particular claim set. Later formulation or method patents can create additional barriers. The FDA Orange Book, USPTO records, and applicable Hatch-Waxman litigation documents are the controlling sources for current launch analysis (FDA, 2024; U.S. Patent and Trademark Office [USPTO], 2024).

What is the Orange Book status of ferric citrate?

Auryxia is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Orange Book listings can include patents directed to the drug substance, formulation, method of use, or other approved product attributes.

For a potential ANDA applicant, the relevant analysis is:

1. Identify every currently listed Auryxia patent.
2. Map each patent to the approved indication and dosage form.
3. Determine whether a Paragraph IV certification is available.
4. Review patent-term adjustment and pediatric extensions.
5. Assess whether the FDA will approve an ANDA before patent expiry.
6. Evaluate the risk of a 30-month stay after patent litigation.
7. Model a launch date under settlement, litigation success, or litigation loss.

A Paragraph IV certification can trigger infringement litigation under the Hatch-Waxman Act. The commercial result may be a 30-month stay, an earlier settlement launch date, or an at-risk launch if the applicant proceeds before final patent resolution.

Which companies are challenging ferric citrate?

Generic competition has centered on manufacturers capable of developing an oral ferric citrate tablet that demonstrates pharmaceutical equivalence and bioequivalence, while also addressing the product’s high active load.

Potential competitive groups include:

• Established generic manufacturers with complex oral-solid-dose capabilities
• Companies with iron-product development expertise
• Contract manufacturers seeking a licensed ANDA platform
• Regional companies pursuing non-U.S. ferric citrate products
• Developers of differentiated oral formats under 505(b)(2)

The relevant competitor screen should include ANDA applicants, patent litigation defendants, settlement counterparties, and companies holding licensed formulation patents. Public litigation records and FDA approval announcements should be reviewed because the identity and timing of applicants can change during the product’s patent life.

What patent litigation affects ferric citrate?

The most important litigation issues are likely to involve:

• Whether the proposed generic product infringes listed formulation claims
• Whether method-of-use claims are valid and enforceable
• Whether the applicant’s label induces infringement
• Whether a proposed product can omit one indication through a skinny label
• Whether ferric citrate composition claims are anticipated or obvious
• Whether manufacturing changes create a noninfringing product
• Whether settlement terms restrict launch timing or authorized-generic competition

Method-of-use claims can be commercially meaningful even when a generic avoids one indication through labeling. A generic applicant may seek approval for hyperphosphatemia while omitting iron-deficiency labeling, or the reverse, depending on the remaining patent claims and FDA requirements.

No definitive commercial conclusion should be drawn from the existence of a patent alone. Claim scope, Orange Book listing status, litigation posture, settlement language, and enforceability determine practical strength.

How strong is the ferric citrate patent estate?

The patent estate is strongest where claims combine a defined ferric citrate composition with a clinically relevant use, dose, or release profile. Broad claims covering ferric citrate as a general phosphate binder face greater validity risk because the compound and its therapeutic uses were publicly studied before the Auryxia approval.

Stronger claim categories

• Defined pharmaceutical compositions with measurable active-content limits
• Particle-size or morphology limitations tied to dissolution or performance
• Formulations that improve tolerability while preserving phosphate binding
• Specific dosing regimens for dialysis or nondialysis CKD
• Combination regimens with clinically demonstrated compatibility
• Manufacturing controls that produce a distinct and reproducible active form

Weaker claim categories

• Routine selection of common tablet excipients
• Broad claims to ferric citrate without technical limitations
• Conventional film coating or compression claims
• Generic treatment claims that substantially overlap earlier publications
• Formulation claims without comparative data

A new excipient platform has greater defensibility when it produces a measurable technical effect, such as lower tablet mass, improved dissolution consistency, reduced free-iron exposure, or a clinically demonstrated reduction in gastrointestinal adverse events.

What generic launch scenarios exist for ferric citrate?

Scenario	Commercial effect
Patent expiry without settlement restrictions	Broad generic entry may follow FDA approval and manufacturing readiness
Paragraph IV settlement with licensed launch	Entry occurs on a negotiated date, often before the latest patent expiry
Litigation win for the generic	Earlier launch and rapid price erosion are possible
Litigation win for the brand	Launch is delayed until patent expiry or later settlement
Skinny-label approval	Generic may enter for a non-patented indication while avoiding another indication
Authorized generic	Brand-controlled generic can reduce the price impact of independent ANDA entry
505(b)(2) differentiated product	Potentially later launch but greater formulation and pricing differentiation

The highest-value commercial asset is a formulation that can enter before broad generic erosion while establishing a clear prescribing or adherence advantage. A smaller tablet alone may not justify premium pricing without evidence of improved persistence or reduced total treatment burden.

What revenue exposure does Auryxia create?

Auryxia revenue is exposed to four commercial variables:

1. Dialysis patient volume.
2. Share of phosphate-binder prescriptions.
3. Iron-deficiency treatment adoption in nondialysis CKD.
4. Generic launch timing and price erosion.

The dialysis indication provides a recurring use case because phosphate binders are taken with meals over long treatment periods. The nondialysis CKD indication expands the addressable population but competes with established oral iron products, intravenous iron, erythropoiesis-stimulating-agent protocols, and evolving CKD treatment standards.

A generic launch would likely affect price, payer coverage, and contracting before it fully eliminates brand demand. A differentiated dosage form could preserve a narrower premium segment, especially for patients with adherence problems, dysphagia, high tablet burden, or intolerance to other phosphate binders.

How does ferric citrate compare with other phosphate binders?

Product class	Main advantage	Main limitation	Excipient opportunity
Ferric citrate	Phosphate binding plus iron delivery	Pill burden, gastrointestinal effects, iron monitoring	Smaller tablets, taste masking, controlled local exposure
Sevelamer	Non-calcium binder with established dialysis use	High pill burden and gastrointestinal effects	Lower-mass tablets, powder, improved dispersion
Sucroferric oxyhydroxide	Lower tablet burden in some regimens	Taste and gastrointestinal tolerability	Chewable taste masking and consistent iron complexation
Calcium-based binders	Low cost and availability	Hypercalcemia and vascular calcification concerns	Modified-release or lower calcium exposure systems
Lanthanum carbonate	Potent phosphate binding	Chewing requirements and gastrointestinal effects	Better chewability and reduced residue

Ferric citrate has a clinically differentiated dual function. That advantage also creates formulation constraints because a new excipient system must preserve both phosphate binding and iron delivery.

What manufacturing and IP barriers affect ferric citrate?

Manufacturing barriers include active-material consistency, iron content uniformity, moisture control, particle-size control, granulation reproducibility, and dissolution testing. The active complex may require tighter controls than a conventional tablet excipient system because changes in ferric citrate characteristics can affect elemental iron delivery and phosphate binding.

Potential IP barriers include:

• Ferric citrate particle engineering
• Specific iron-to-citrate ratios
• Solid-state or coordination-state characteristics
• Granulation and compression processes
• Coated multiparticulate systems
• Dose-reduction methods
• Formulations with reduced gastrointestinal exposure
• Product-by-process claims supported by distinct performance data

A manufacturer should avoid relying only on excipient substitutions. A stronger freedom-to-operate strategy combines independent composition claims, a noninfringing manufacturing process, and a label that avoids patented methods of use.

What are the best commercial opportunities for excipient suppliers?

The most attractive opportunities are specialty excipients that solve a documented product problem without materially increasing tablet size.

Priority opportunities include:

1. High-efficiency compression systems for high active-load tablets.
2. Taste-masking coatings for chewable or dispersible ferric citrate.
3. Moisture-barrier films that preserve stability without delaying release.
4. Disintegrant systems optimized for iron-complex tablets.
5. Multiparticulate carriers that reduce local iron concentration.
6. Excipient platforms supported by comparative dissolution and tolerability data.
7. Co-development agreements with generic or 505(b)(2) manufacturers.
8. Licensed formulation technology for regional ferric citrate products.

The best licensing targets are formulation technologies with prior use in high-load mineral, iron, or phosphate-binding products. Suppliers should package excipient supply with formulation development, process transfer, analytical methods, and patent rights. Commodity excipient supply alone is unlikely to create durable pricing power.

Key Takeaways

• Ferric citrate is a dual-purpose oral therapy for phosphate control and iron delivery.
• Auryxia’s high active load creates a clear opportunity for tablet-size and pill-burden reduction.
• The most commercially relevant excipient functions are compression, disintegration, taste masking, moisture protection, and local iron-exposure control.
• Chewable, granule, sachet, and sprinkle formats are potential differentiated products, but taste and phosphate-binding performance are central barriers.
• Generic entry depends on Orange Book listings, Paragraph IV certifications, litigation, and settlement terms.
• Formulation patents are stronger when supported by measurable technical effects and clinical evidence.
• Excipient suppliers have the greatest opportunity through co-development and licensing rather than commodity sales.
• Ferric citrate’s commercial defense depends on adherence, tolerability, tablet burden, and indication-specific prescribing after generic entry.

FAQs

Can ferric citrate be formulated as a liquid?

Yes, but a liquid product would need to address taste, suspension stability, dose uniformity, iron staining, and compatibility with food and other medicines. A liquid may be more suitable for selected dysphagia populations than for routine dialysis use.

Can ferric citrate use enteric coating?

An enteric coating is technically possible, but it may be counterproductive because phosphate binding is intended to occur during gastrointestinal transit and is administered with meals. Any enteric approach would require evidence that delayed release preserves clinical activity.

Is a ferric citrate chewable product likely to receive automatic generic substitution?

No. A chewable or otherwise materially different dosage form may require a separate regulatory pathway, depending on its composition, labeling, pharmaceutical equivalence, and FDA classification.

Which excipient is most important for reducing ferric citrate tablet size?

A high-efficiency compression system is usually more important than any single excipient. Microcrystalline cellulose and coprocessed compression excipients can improve tablet strength, but the active-material particle properties and granulation process often determine the final tablet dimensions.

Can an excipient patent delay generic ferric citrate entry?

Yes, if the patent claims an approved formulation or method of use, is listed in the Orange Book where applicable, and survives validity, enforceability, and infringement challenges. An excipient patent that is not tied to the approved product may have less direct Hatch-Waxman impact.

References

Akebia Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

U.S. Food and Drug Administration. (2024). Auryxia (ferric citrate) prescribing information. FDA.

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.

U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System. USPTO.